EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study ( OPERA‐C )

Paul J Clark, Patricia C Valery iD, Simone I Strasser, Martin Weltman, Alex Thompson, Miriam T Levy, Barbara Leggett, Amany Zekry, Julian Rong, Marie Sinclair, Jacob George, William Sievert und 6 weitere

Drug and Alcohol Review · 2024

DOI: 10.1111/dar.13914 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Drug and Alcohol Review, 2024. Verfasst von Paul J Clark und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Alcohol and Drug Assessment Unit, Princess Alexandra and Mater Hospitals, Brisbane, Australia. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Alcohol Drinking, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Commonwealth Department of Health, the Gastroenterological Society of Australia (GESA), Gilead Sciences, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alcohol use is common in patients with chronic hepatitis C virus (HCV) infection. We examined the impact of alcohol use on direct‐acting antiviral (DAA) therapy outcome and the clinical course of liver disease and 2‐year survival for patients receiving HCV DAA therapy.

Methods

Adults ( n = 2624) recruited from 26 Australian hospital liver clinics during 2016–2021 were followed up for 2 years. Risky alcohol use was defined by a combination of self‐report (≥40 g/day of ethanol), physician‐reported history of problematic alcohol use, and anti‐craving medication prescription via population‐based database linkage. We examined factors associated with advanced liver fibrosis and survival using multivariable logistic and Cox regression.

Results

Among 1634 patients (62.3%) with risky alcohol use, 24.6% reported consuming ≥40 g/day of alcohol, 98.3% physician‐reported problematic alcohol use; only 4.1% were dispensed naltrexone/acamprosate. One hundred and forty‐three patients with cirrhosis reported ≥40 g/day of alcohol, 6 (4.3%) were prescribed naltrexone/acamprosate. Risky alcohol use was associated with advanced fibrosis (adjusted‐odds ratio 1.69, 95% confidence interval 1.32–2.17) and patients were over‐represented for cirrhosis (45.1% vs. 25.6% in no‐risky alcohol use [ p < 0.001]) and hepatocellular carcinoma (5.7% vs. 2.5% [ p < 0.001]). Sustained viral response ( p = 0.319) and 2‐year survival (adjusted‐hazard ratio 1.98, 95% confidence interval 0.84–4.63) after DAA therapy were not associated with risky alcohol use. Discussion and Conclusions Risky alcohol use in HCV patients was prevalent, but did not reduce HCV cure. Treatment for alcohol dependence was low. Risky alcohol use may be under‐recognised in liver clinics. Better integration of addiction medicine into liver services and increased resourcing and addiction medicine training opportunities for hepatologists may help address this.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsAlcohol DrinkingLiver CirrhosisHumansMaleFemaleMiddle AgedAustraliaProspective StudiesAdultTreatment OutcomeAgedDisease ProgressionRisk Factors

Stichwörter der Autor:innen

alcohol dependencealcohol‐use disordercirrhosisliver fibrosismortality

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Alcohol and Drug Assessment Unit, Princess Alexandra and Mater Hospitals, Brisbane, Australia.
  • Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia.
  • Hepatology Services, Nepean Hospital, Sydney, Australia.
  • Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia.

ORCID-Profile: Patricia C Valery

Förderung

  • Commonwealth Department of Health, the Gastroenterological Society of Australia (GESA)
  • Gilead Sciences
  • Merck
  • Abbvie
  • Robert W. Storr Bequest
  • Sydney Medical Foundation, University of Sydney
  • A National Health and Medical Research Council of Australia (NHMRC) Program
  • Project, Ideas, and Investigator

Zitieren

APA

Clark, P. J., Valery, P. C., Strasser, S. I., Weltman, M., Thompson, A., Levy, M. T., Leggett, B., Zekry, A., Rong, J., Sinclair, M., George, J., Sievert, W., MacQuillan, G., Tse, E., Nicoll, A., Wade, A., Cheng, W., & Roberts, S. K. (2024). Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study ( OPERA‐C ). Drug and Alcohol Review. https://doi.org/10.1111/dar.13914

Vancouver

Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson A, Levy MT, et al. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study ( OPERA‐C ). Drug and Alcohol Review. 2024. doi:10.1111/dar.13914

BibTeX
@article{Clark2024,
  author = {Clark, Paul J and Valery, Patricia C and Strasser, Simone I and Weltman, Martin and Thompson, Alex and Levy, Miriam T and Leggett, Barbara and Zekry, Amany and Rong, Julian and Sinclair, Marie and George, Jacob and Sievert, William and MacQuillan, Gerry and Tse, Edmund and Nicoll, Amanda and Wade, Amanda and Cheng, Wendy and Roberts, Stuart K},
  title = {Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study ( OPERA‐C )},
  journal = {Drug and Alcohol Review},
  year = {2024},
  doi = {10.1111/dar.13914}
}
Kostenlos starten →